Record-Breaking Price Movement
On 20 Jul 2026, Parmax Pharma Ltd’s share price opened and traded at Rs.102.92, setting a new 52-week and all-time high. This price represents a substantial increase from its 52-week low of Rs.22.60, translating to a remarkable 355.40% rise from the lowest point within the past year. The stock’s performance on the day was strong, registering a 1.99% gain, while the Sensex declined by 0.54%, underscoring Parmax Pharma’s relative strength in the current market environment.
Consistent Uptrend and Outperformance
The stock has demonstrated a persistent upward trajectory, gaining for 21 consecutive trading days. Over this period, Parmax Pharma delivered a total return of 51.31%, significantly outpacing the Pharmaceuticals & Biotechnology sector by 1.19% on the day of the new high. The stock’s momentum is further highlighted by its performance across multiple time frames: a 10.31% gain over the past week, 48.34% over the last month, and an extraordinary 203.60% increase over the past three months. These figures contrast sharply with the Sensex, which posted modest or negative returns over the same intervals.
Long-Term Performance Context
Examining longer-term returns, Parmax Pharma Ltd has outperformed the broader market indices consistently. Year-to-date, the stock surged by 204.23%, while the Sensex declined by 8.79%. Over one year, the stock appreciated by 151.88% compared to the Sensex’s 4.93% decline. Even over a three-year horizon, Parmax Pharma’s 243.07% gain dwarfs the Sensex’s 15.03% rise. However, over five years, the stock’s 71.96% gain, though substantial, trails the Sensex’s 48.91% increase, and the company has no recorded price movement over a ten-year span.
Technical Indicators Confirm Bullish Momentum
The technical outlook for Parmax Pharma Ltd remains strongly bullish. The current trend shifted to bullish on 8 Jun 2026 at a price of Rs.48.81, marking a clear change from a mildly bullish phase. Key technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory all signal bullish momentum on both weekly and monthly time frames. The stock is trading above all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing the strength of the current uptrend.
Immediate support is established at the 52-week low of Rs.22.60, while resistance levels previously noted at Rs.84.23 (20-day moving average), Rs.45.01 (100-day moving average), and Rs.39.09 (200-day moving average) have been decisively surpassed. The new all-time high at Rs.102.92 now represents a far resistance level, setting a fresh benchmark for the stock.
Valuation and Financial Metrics
Despite the impressive price appreciation, Parmax Pharma Ltd remains a loss-making entity, with valuation multiples reflecting this status. The price-to-earnings ratio is not applicable due to negative earnings, and the price-to-book value stands at -6.14x. Enterprise value multiples such as EV/EBITDA and EV/EBIT are also negative at -13.58x and -10.57x respectively, while EV/Sales is 4.02x and EV/Capital Employed is 10.30x. The company does not currently pay dividends, with no dividend yield or payout recorded.
Quality and Financial Trend Assessment
Parmax Pharma Ltd’s overall quality grade is below average, reflecting challenges in long-term financial performance. The company has experienced negative growth in sales and EBIT over the past five years, with sales declining by 14.30% and EBIT by 225.63%. The average EBIT to interest coverage ratio is weak at 0.66x, though the company benefits from a net cash position with negative net debt and no promoter share pledging. Return on capital employed (ROCE) and return on equity (ROE) remain subdued at -28.89% and 5.12% respectively.
Short-term financial trends show mixed signals. The latest quarterly earnings per share (EPS) reached a high of Rs.-1.55, while profit after tax (PAT) for the nine-month period declined by 50.12% to Rs.-3.39 crores. Net sales for the latest six months also decreased by 31.23% to Rs.7.64 crores. Debtors turnover ratio is at a low 3.83 times, and profit before tax excluding other income for the quarter is at a low of Rs.-2.30 crores.
Delivery Volumes and Market Activity
Market activity has intensified alongside the price rally. Delivery volumes have increased significantly, with a 29.52% rise over the past month and an 85.38% increase in delivery volume on the day of the new high compared to the five-day average. This heightened trading interest accompanies the stock’s sustained gains and technical strength.
Summary of Market Position
Parmax Pharma Ltd’s stock reaching an all-time high of Rs.102.92 on 20 Jul 2026 represents a notable milestone in its market journey. The stock’s strong performance over multiple time frames, combined with bullish technical indicators and increased trading volumes, highlights a period of significant momentum. While the company’s financial fundamentals and quality metrics indicate areas for improvement, the stock’s price action underscores a phase of robust market recognition within the Pharmaceuticals & Biotechnology sector.
